got out of LABD to buy LABU on next pullback down to about $88.40 earnings growth and M&A optimism to reestablish in biotech/ healthcare. watching that ceiling of resistance to potentially pull profits
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
